Disease · MONDO_0005362

erectile dysfunction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. erectile dysfunction. Diseases, record MONDO_0005362. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005362

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: erectile dysfunction; Open Targets
Open Targets ID: MONDO_0005362; Open Targets
Other names: Difficulty getting a full erection, Difficulty getting an erection, Impotence, erectile dysfunction (disease), male erectile Disorder, male impotence, male sexual impotence, sexual impotence (finding); Open Targets
Disease Ontology: DOID:1875; Disease Ontology
MeSH: D007172; MeSH
NCI Thesaurus: C34801; NCI Thesaurus
Highest stage of its drugs: Approval, for 13 of its 69 drugs, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs69

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TADALAFIL	CHEMBL779	Small molecule	Approval	ATC, DailyMed, EMA Human Drugs, PMDA and TTD	82	64	64	Drugs and targets
VARDENAFIL	CHEMBL1520	Small molecule	Approval	ATC, EMA Human Drugs and TTD	56	52	52	Drugs and targets
SILDENAFIL	CHEMBL192	Small molecule	Approval	ATC, EMA Human Drugs and TTD	53	44	44	Drugs and targets
SILDENAFIL CITRATE	CHEMBL1737	Small molecule	Approval	DailyMed	36	20	20	Drugs and targets
UDENAFIL	CHEMBL2103849	Small molecule	Approval	ATC and TTD	14	12	12	Drugs and targets
AVANAFIL	CHEMBL1963681	Small molecule	Approval	ATC, EMA Human Drugs, FDA and TTD	14	10	10	Drugs and targets
ALPROSTADIL	CHEMBL495	Small molecule	Approval	ATC, DailyMed and TTD	15	8	8	Drugs and targets
PAPAVERINE	CHEMBL19224	Small molecule	Approval	ATC	5	3	3	Drugs and targets
YOHIMBINE	CHEMBL15245	Small molecule	Approval	ATC and TTD	3	1	1	Drugs and targets
VARDENAFIL HYDROCHLORIDE	CHEMBL1339	Small molecule	Approval	DailyMed and PMDA	15	0	0	Drugs and targets

1 to 10 of 69

See all 69 drugs

Targets134

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDE5A	3',5'-cyclic phosphodiesterase	9	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor	Approval	https://conductscience.org/library/genes/8654	Drugs and targets
ADRA1A	Adrenergic receptor alpha	5	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	5	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	5	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	5	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	4	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2/3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA2A	Adrenergic receptor alpha	3	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	3	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	3	Adrenergic receptor alpha antagonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 2	https://conductscience.org/library/genes/2057	Drugs and targets

1 to 10 of 134

See all 134 targets

Trials226

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01937871	A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)	Phase 3	909	2017-02-07	Benign Prostate Hyperplasia, Erectile Dysfunction	TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT01122264	A Study in Patients With Erectile Dysfunction	Phase 4	770	2012-10-19	Erectile Dysfunction	SILDENAFIL CITRATE, TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT00853606	Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction	Phase 3	712	2012-06-28	Erectile Dysfunction	AVANAFIL	Its record names the disease	ClinicalTrials.gov
NCT00790751	Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED	Phase 3	646	2012-06-28	Erectile Dysfunction	AVANAFIL	Its record names the disease	ClinicalTrials.gov
NCT02224846	A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction	Phase 4	635	2017-10-27	Erectile Dysfunction	TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT01130532	A Study in Erectile Dysfunction	Phase 4	623	2013-01-04	Erectile Dysfunction	TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT01037244	Treatment of Erectile Dysfunction I	Phase 3	618	2011-12-22	Erectile Dysfunction	UDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT00855582	A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia	Phase 3	606	2011-06-30	Erectile Dysfunction, Benign Prostatic Hyperplasia	TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT01037218	Treatment of Erectile Dysfunction II	Phase 3	601	2011-12-22	Erectile Dysfunction	UDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT01026818	A Study of Tadalafil After Radical Prostatectomy	Phase 4	583	2013-11-14	Erectile Dysfunction	TADALAFIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 226

See all 226 trials

Comparisons in its trials32

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
2.5 mg/5 mg Tadalafil vs 5 mg Tadalafil: serious adverse events	15 of 210	17 of 421	631	NCT02224846	Trial comparisons
PDE5I + PLACEBO vs PDE5I + DPX: serious adverse events	4 of 245	3 of 250	495	NCT01063855	Trial comparisons
MED2005 vs MED Placebo: deaths from any cause	0 of 229	0 of 227	456	NCT02495467	Trial comparisons
MED2005 vs MED Placebo: serious adverse events	0 of 229	0 of 227	456	NCT02495467	Trial comparisons
MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1	94 of 216	56 of 216	432	NCT02495467	Trial comparisons
MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2	85 of 216	54 of 216	432	NCT02495467	Trial comparisons
Vardenafil ODT (STAXYN, BAY 38-9456) vs Placebo: serious adverse events	4 of 184	1 of 174	358	NCT00631969	Trial comparisons
Vardenafil ODT (STAXYN, BAY38-9456) vs Placebo: serious adverse events	2 of 171	1 of 166	337	NCT00655629	Trial comparisons
Tadalafil vs Placebo: serious adverse events	2 of 147	1 of 70	217	NCT00836693	Trial comparisons
MED3000 vs Tadalafil: deaths from any cause	0 of 94	0 of 94	188	NCT04984993	Trial comparisons

1 to 10 of 32

See all 32 comparisons in its trials

Papers from its trials52

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30777468	RESULT	1	PubMed
29145685	RESULT	1	PubMed
27151768	RESULT	1	PubMed
26311340	RESULT	1	PubMed
26134065	RESULT	1	PubMed
22790642	RESULT	2	PubMed
22354624	RESULT	1	PubMed
22248153	RESULT	1	PubMed
21911624	RESULT	1	PubMed
21883954	RESULT	2	PubMed

1 to 10 of 52

See all 52 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005362

GET https://conductscience.org/api/diseases/v1/MONDO_0005362/drugs?page=2

API reference For AI assistants